LOTEMAX is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as:
- allergic conjunctivitis
- acne rosace
- superficial punctate keratitis
- herpes zoster keratitis
- selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.
- LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery.
LOTEMAX is less effective than some other topical steroids we use, however, it also is associated with fewer side effects. LOTEMAX should not be used in patients who require a more potent corticosteroid; most commonly, this is in patients with anterior uveitis.
How its supplied: 5 ml, 10 ml and 15 ml suspension (requires shaking prior to each use) and 3.5 gm ointment
Pregnancy: (Category C) LOTEMAX should be used during pregnancy only if the potential
benefit justifies the potential risk to the embryo or fetus.
Children: Safety and effectiveness in pediatric patients have not been established
Important Product Risk Information
- LOTEMAX is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures. LOTEMAX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
- Prolonged use of LOTEMAX is associated with several warnings and precautions, including glaucoma with optic nerve damage, defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular infections (including herpes simplex), delay in wound healing and increase in bleb formation.
- If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids
- Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% – 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia
- Please see complete information regarding CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in the accompanying LOTEMAX full prescribing information by clicking the link below
For additional product description and warnings click here: